Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life
Open Access
- 1 February 2025
- journal article
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 4 (2) , pgaf042
Abstract
Most therapeutic antibodies are based on immunoglobulin G (IgG) due to their potent effector functions and long plasma half-life. However, also monomeric IgA has emerged as an attractive candidate for cancer treatment as, upon specific binding to tumor cells, it can activate myeloid cells, like polymorphonuclear leukocytes and macrophages, to kill the tumor cells by engaging the Fc α receptor I (FcαRI). Despite this favorable property, human IgA has a short plasma half-life in both mice and humans, which is clearly limiting preclinical studies in a translational perspective. Here, we report on albumin-equipped designs of human IgA antibodies that are long acting due to tailored binding to the human form of neonatal Fc receptor (FcRn), which is a natural plasma half-life regulator of albumin. Importantly, this was achieved without compromising the ability of IgA to engage and activate FcαRI-expressing effector cells for tumor cell killing in vitro and in vivo in a new mouse model transgenic for the human forms of FcRn and FcαRI. We further show that the potency of the engineered long-acting human IgA against tumor cells with intermediate target antigen expression levels could be enhanced by myeloid checkpoint inhibitors targeting the signal regulatory protein α-CD47 axis.Keywords
Funding Information
- Norwegian Cancer Society (223315)
- Research Council of Norway (314909, 287927, 335688)
- South-Eastern Norway Regional Health Authority (2018052, 2021069, 2024046, 7650, 11944)
- German Research Foundation (5010, 444949889)
This publication has 96 references indexed in Scilit:
- Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18).1999
- The Glycosylation and Structure of Human Serum IgA1, Fab, and Fc Regions and the Role of N-Glycosylation on Fcα Receptor InteractionsJournal of Biological Chemistry, 1998
- Identification of critical IgG binding epitopes on the neonatal Fc receptorJournal of Molecular Biology, 1997
- FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.1997
- A NEW CONCEPT FOR MACROMOLECULAR THERAPEUTICS IN CANCER-CHEMOTHERAPY - MECHANISM OF TUMORITROPIC ACCUMULATION OF PROTEINS AND THE ANTITUMOR AGENT SMANCS1986
- Proportions and identity of IgA1-degrading bacteria in periodontal pockets from patients with juvenile and rapidly progressive periodontitisJournal of Periodontal Research, 1986
- COMPARATIVE ASPECTS OF THE HEPATOBILIARY TRANSPORT OF IgA*Annals of the New York Academy of Sciences, 1983
- Changes in size, subclass, and metabolic properties of serum immunoglobulin A in liver diseases and in other diseases with high serum immunoglobulin A.Journal of Clinical Investigation, 1983
- IgA interaction with the asialoglycoprotein receptor.Proceedings of the National Academy of Sciences, 1982
- Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndromeJournal of Clinical Investigation, 1971